Abstract:Biofilms formed by methicillin-resistant Staphylococcus aureus (MRSA) are one of the contributing factors to recurrent nosocomial infection in humans. There is currently no specific treatment targeting on biofilms in clinical trials approved by FDA, and antibiotics remain the primary therapeutic strategy. In this study, two anthraquinone compounds isolated from a rare actinobacterial strain Kitasatospora albolonga R62, 3,8-dihydroxy-l-methylanthraquinon-2-carboxylic acid ( 1 ) and 3,6,8-trihydroxy-1-methylanthraquinone-2-carboxylic acid ( 2 ), together with their 10 commercial analogs 3 – 12 were evaluated for antibacterial and antibiofilm activities against MRSA, which led to the discovery of two potential antibiofilm anthraquinone compounds anthraquinone-2-carboxlic acid ( 6 ) and rhein ( 12 ). The structure-activity relationship analysis of these anthraquinones indicated that the hydroxyl group at the C-2 position of the anthraquinone skeleton played an important role in inhibiting biofilm formation at high concentrations, while the carboxyl group at the same C-2 position had a great influence on the antibacterial activity and biofilm eradication activity. The results of crystal violet and methyl thiazolyl tetrazolium staining assays, as well as scanning electron microscope and confocal scanning laser microscopy imaging of compounds 6 and 12 treatment groups showed that both compounds could disrupt preformed MRSA biofilms possibly by killing or dispersing biofilm cells. RNA-Seq was subsequently used for the preliminary elucidation of the mechanism of biofilm eradication, and the results showed upregulation of phosphate transport-related genes in the overlapping differentially expressed genes of both compound treatment groups. Herein, we propose that anthraquinone compounds 6 and 12 could be considered promising candidates for the development of antibiofilm agents.

Study on Bioactive Antibacterial Activty of Anthraquinones Produced from Marine Actinomyces WBF16

Bioactive Polycyclic Quinones from Marine Streptomyces Sp. 182SMLY.

Study on Bioactive Alkaloids Ingredient Produced by Marine Actinomyces N331

Preliminary Research of Bioactive Metabolite Produced by Marine Actinomyces M326

Preliminary Study on the Antibiotic Active Metabolites Produced by Marine Actinomyces M324

Antibacterial Activity of Broth of Marine Actinomycete WB-F5 and Isolation and Identification of Its Anti-bacterial Substances

Bioactive Staurosporine Derivatives from the Streptomyces Sp. NB-A13.

Three New Isoflavonoid Glycosides From The Mangrove-Derived Actinomycete Micromonospora Aurantiaca 110b

Aureolic Acids from A Marine-Derived Streptomyces Sp Wbf16

Isolation and identification of secondary metabolites from marine-derived actinomycete WBF16

Anthraquinones as Potential Antibiofilm Agents Against Methicillin-Resistant Staphylococcus aureus

[Relationship Between Antibacterial Activity of Aloe and Its Anthaquinone Compounds].

Separation, Purification, and Structural Identification of Antitumor Active Components from Marine Actinomycete ACMA006

Anthraquinone Derivatives From A Marine-Derived Fungus Sporendonema Casei Hdn16-802

Bioactive cytochalasans from the fungus Arthrinium arundinis DJ-13

Bioactive Alkaloids from Sponge-Derived Actinomyces Sh6004

Purification and structure elucidation of antifungal bioactive metabolites from marine actinomycete Y12-26

Cytotoxic and antimicrobial activities of secondary metabolites isolated from the deep-sea-derived Actinoalloteichus cyanogriseus 12A22

Studies on the Antitumor Constituents of Marine Sponge Derived Actinomycete SH6004

Research Progress in Anthracycline Compounds Produced by Marine Actinomycetes

Antibacterial Anthraquinone Derivatives from a Sea Anemone-Derived Fungus Nigrospora sp.